• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CellMax Life Announces Expansion of Company Board With Leading Industry Experts

    4/6/23 9:00:00 AM ET
    $EXAS
    $HOLX
    Medical Specialities
    Health Care
    Medical Electronics
    Health Care
    Get the next $EXAS alert in real time by email

    Renowned industry experts join to aid in preparation around premarket approval for FirstSight

    SUNNYVALE, Calif., April 6, 2023 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the appointment of Stanley N. Lapidus (Stan) as an advisory board member and Ronnie (Ron) Andrews as an independent board member. The announcement comes only one month after CellMax Life expanded its GI advisory board with luminaries in the GI arena.

    "Both Stan and Ron are pioneers in the diagnostics industry, with unique perspectives and proven track records of success," said Atul Sharan, CEO of CellMax Life. Stan is one of the most successful innovators and leaders in cancer diagnostics, and it is a privilege to have him join CelMax's advisory board. Ron's scientific expertise and extensive background in commercializing diagnostic tests will greatly enable execution of the regulatory and marketing strategies for our FirstSight colorectal cancer screening blood test."

    Each new board member brings a wealth of experience:

    • Stan Lapidus is an inventor and entrepreneur who currently serves on a number of healthcare and medical technology boards. He was the founding CEO of three medical diagnostics companies: Cytyc Corp., acquired by Hologic Inc. (NASDAQ:HOLX), which revolutionized early detection of cervical cancer, and Exact Sciences (NASDAQ:EXAS), which pioneered the noninvasive early detection of colorectal cancer. He holds 37 patents, primarily in methods for early detection of cancer, and served as an instructor at MIT where he taught graduate-level courses on clinical trials. The two ThinPrep prototypes developed at Cytyc are displayed at the Smithsonian National Museum of American History.
    • Ron Andrews has more than 35 years of experience in the diagnostics industry. He served as CEO of two precision diagnostic companies, Clarient Inc., acquired by GE Healthcare, and Oncocyte Corp., and held corporate leadership positions at ThermoFisher/Life Technologies, Roche Molecular Diagnostics, and GE Healthcare. Through these experiences, Ron brings deep expertise in commercializing molecular diagnostics and is a dynamic and respected leader in the medical device industry.

    "I've spent most of my career focused on the early detection of cancer and am excited and impressed by CellMax Life's progress with its FirstSight blood test," said Stan Lapidus. "The recent study data at ASCO GI 2023 displays the technology platform's unique ability to detect colorectal cancer and advanced adenomas with a high degree of sensitivity, which is critical to the ultimate goal of eradicating this preventable cancer."

    "Colorectal cancer is one of the most preventable cancers, yet it is the second most common cause of death. A noninvasive screening blood test that detects both colorectal cancer and advanced adenomas has the potential to increase patient adherence for screening and in turn, decrease both incidence and mortality," said Ron Andrews. "Being able to have a hand in the regulatory approval pathway for FirstSight, which has demonstrated high sensitivity in an intended use population, solidified my personal commitment to the company and its mission to change how we detect and manage cancer."

    For more information about CellMax Life and its FirstSight test, visit cellmaxlife.com.

    About CellMax Life:

    CellMax Life is a diagnostics company focused on cancer screening with proprietary technology for detecting precancerous and cancer cells and genomic aberrations in a single blood sample. CellMax Life is headquartered in Sunnyvale, California. For more information, visit http://www.cellmaxlife.com.

    Media Contact

    Stephen Su, Cellmax Life, 1 408-887-7640, [email protected]

     

    SOURCE Cellmax Life

    Get the next $EXAS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EXAS
    $HOLX

    CompanyDatePrice TargetRatingAnalyst
    Exact Sciences Corporation
    $EXAS
    4/10/2025$60.00Outperform
    Mizuho
    Exact Sciences Corporation
    $EXAS
    3/13/2025$52.00Sector Perform
    RBC Capital Mkts
    Hologic Inc.
    $HOLX
    3/3/2025Buy → Hold
    Argus
    Hologic Inc.
    $HOLX
    2/6/2025$80.00 → $75.00Outperform → Market Perform
    Leerink Partners
    Hologic Inc.
    $HOLX
    2/3/2025Buy → Hold
    Needham
    Exact Sciences Corporation
    $EXAS
    1/23/2025$70.00Overweight
    Barclays
    Hologic Inc.
    $HOLX
    12/13/2024Peer Perform
    Wolfe Research
    Hologic Inc.
    $HOLX
    12/10/2024$90.00Buy
    Needham
    More analyst ratings

    $EXAS
    $HOLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Exact Sciences to Participate in May Investor Conference

      Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. BofA Securities Health Care Conference, Las Vegas Fireside chat on Wednesday, May 14, 2025 at 1:40 p.m. ET (10:40 a.m. PT) The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the suc

      5/2/25 6:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Announces First-Quarter 2025 Results

      First quarter highlights Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core revenue basis, including Screening revenue of $540 million and Precision Oncology revenue of $167 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $40 million and $15 million, respectively Launched the Cologuard Plus™ test, the company's next-generation colon cancer screening test Presented data in the Journal of Surgical Oncology demonstrating the clinical strength of the Oncodetect™ test, the company's molecular residual disease ("MRD") and recurrence monitoring test Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of canc

      5/1/25 4:05:00 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Hologic Announces Financial Results for Second Quarter of Fiscal 2025

      – Revenue of $1,005.3 Million Slightly Exceeds Guidance – – Company Reports GAAP Diluted EPS of ($0.08); Non-GAAP Diluted EPS of $1.03 at High End of Guidance – – Company Maintains Annual Revenue Guidance, Lowers Guidance for GAAP and Non-GAAP EPS – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal second quarter ended March 29, 2025. "We delivered on our financial commitments in the second quarter," said Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer. "Both revenue and non-GAAP EPS finished at the high ends of our guidance ranges, driven by our diagnostics and skeletal businesses, strong profitability, share

      5/1/25 4:01:00 PM ET
      $HOLX
      Medical Electronics
      Health Care

    $EXAS
    $HOLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Hologic Inc.

      SC 13G/A - HOLOGIC INC (0000859737) (Subject)

      11/14/24 1:28:29 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • SEC Form SC 13G filed by Exact Sciences Corporation

      SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

      11/13/24 2:58:53 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Exact Sciences Corporation

      SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

      11/8/24 10:52:39 AM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    $HOLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Exact Sciences with a new price target

      Mizuho initiated coverage of Exact Sciences with a rating of Outperform and set a new price target of $60.00

      4/10/25 12:41:36 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • RBC Capital Mkts initiated coverage on Exact Sciences with a new price target

      RBC Capital Mkts initiated coverage of Exact Sciences with a rating of Sector Perform and set a new price target of $52.00

      3/13/25 7:36:02 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Hologic downgraded by Argus

      Argus downgraded Hologic from Buy to Hold

      3/3/25 8:06:16 AM ET
      $HOLX
      Medical Electronics
      Health Care

    $EXAS
    $HOLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 29, 2024 - FDA Roundup: October 29, 2024

      For Immediate Release: October 29, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA responded to objections on the agency’s final rule that removed the authorized food contact uses of most phthalates because industry abandoned these uses. The FDA evaluated the objections and concluded that they did not provide a basis for mod

      10/29/24 3:30:19 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • February 2, 2024 - FDA Roundup: February 2, 2024

      For Immediate Release: February 02, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a safety communication to warn consumers, health care providers, and health care facilities not to use certain Cardinal Health Monoject luer-lock and enteral syringes. Dimensional changes made to the syringes, when used with syringe pump

      2/2/24 3:58:21 PM ET
      $HOLX
      Medical Electronics
      Health Care

    $EXAS
    $HOLX
    Financials

    Live finance-specific insights

    See more
    • Exact Sciences Announces First-Quarter 2025 Results

      First quarter highlights Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core revenue basis, including Screening revenue of $540 million and Precision Oncology revenue of $167 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $40 million and $15 million, respectively Launched the Cologuard Plus™ test, the company's next-generation colon cancer screening test Presented data in the Journal of Surgical Oncology demonstrating the clinical strength of the Oncodetect™ test, the company's molecular residual disease ("MRD") and recurrence monitoring test Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of canc

      5/1/25 4:05:00 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Hologic Announces Financial Results for Second Quarter of Fiscal 2025

      – Revenue of $1,005.3 Million Slightly Exceeds Guidance – – Company Reports GAAP Diluted EPS of ($0.08); Non-GAAP Diluted EPS of $1.03 at High End of Guidance – – Company Maintains Annual Revenue Guidance, Lowers Guidance for GAAP and Non-GAAP EPS – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal second quarter ended March 29, 2025. "We delivered on our financial commitments in the second quarter," said Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer. "Both revenue and non-GAAP EPS finished at the high ends of our guidance ranges, driven by our diagnostics and skeletal businesses, strong profitability, share

      5/1/25 4:01:00 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • Hologic to Announce Financial Results for the Second Quarter of Fiscal 2025 on Thursday, May 1, 2025

      Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2025 on Thursday, May 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 6553890. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at investors.hologic.c

      4/3/25 4:30:00 PM ET
      $HOLX
      Medical Electronics
      Health Care

    $EXAS
    $HOLX
    Leadership Updates

    Live Leadership Updates

    See more
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

      CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B

      2/6/25 8:30:00 AM ET
      $EXAS
      $GE
      $GMED
      $XRAY
      Medical Specialities
      Health Care
      Consumer Electronics/Appliances
      Technology
    • Biote Announces CEO Retirement and Succession Plan

      Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

      1/30/25 4:10:00 PM ET
      $BTMD
      $HOLX
      $MYGN
      $PODD
      Medicinal Chemicals and Botanical Products
      Health Care
      Medical Electronics
      Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $EXAS
    $HOLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Madaus Martin D bought $300,760 worth of shares (5,445 units at $55.24) (SEC Form 4)

      4 - HOLOGIC INC (0000859737) (Issuer)

      5/9/25 4:39:33 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • President and CEO Conroy Kevin T bought $1,001,325 worth of shares (19,500 units at $51.35), increasing direct ownership by 2% to 1,074,191 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      11/13/24 12:56:28 PM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    $HOLX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Hologic Inc.

      10-Q - HOLOGIC INC (0000859737) (Filer)

      5/2/25 8:05:04 AM ET
      $HOLX
      Medical Electronics
      Health Care
    • SEC Form 10-Q filed by Exact Sciences Corporation

      10-Q - EXACT SCIENCES CORP (0001124140) (Filer)

      5/1/25 5:08:20 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - EXACT SCIENCES CORP (0001124140) (Filer)

      5/1/25 4:06:17 PM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    $HOLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Madaus Martin D bought $300,760 worth of shares (5,445 units at $55.24) (SEC Form 4)

      4 - HOLOGIC INC (0000859737) (Issuer)

      5/9/25 4:39:33 PM ET
      $HOLX
      Medical Electronics
      Health Care
    • SVP, General Counsel & Sec Herriott James was granted 363 shares, increasing direct ownership by 2% to 15,585 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      5/8/25 4:30:09 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • New insider Liddy Anne M. claimed ownership of 11,426 shares (SEC Form 3)

      3 - HOLOGIC INC (0000859737) (Issuer)

      5/2/25 4:52:34 PM ET
      $HOLX
      Medical Electronics
      Health Care